Cargando…
A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) with in vitro pro-apoptotic and antiangiogenic effects on chronic lymphocytic leukemia (CLL) cells. As monotherapy in patients with CLL, it has no clinical activity. Here we report the results of an open-label,...
Autores principales: | Kay, Neil E., Strati, Paolo, LaPlant, Betsy R., Leis, Jose F., Nikcevich, Daniel, Call, Timothy G., Pettinger, Adam M., Lesnick, Connie E., Hanson, Curtis A., Shanafelt, Tait D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346637/ https://www.ncbi.nlm.nih.gov/pubmed/27861157 http://dx.doi.org/10.18632/oncotarget.13412 |
Ejemplares similares
-
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022) -
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022) -
The specific heat of the human body is lower than previously believed: The journal Temperature toolbox
por: Xu, Xiaojiang, et al.
Publicado: (2022) -
Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011) -
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
por: Kumar, Shaji K., et al.
Publicado: (2018)